Denali Therapeutics (DNLI) Current Assets (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Current Assets data on file, last reported at $1.0 billion in Q1 2026.

• Current Assets for Q1 2026 came in at $1.0 billion, up 16.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 16.4% YoY), and the FY2025 annual result was $900.7 million, up 4.19% from the prior year.
• Current Assets improved to $1.0 billion in Q1 2026 per DNLI's latest filing, from $900.7 million in the prior quarter.
• Over five years, Current Assets peaked at $1.4 billion in Q4 2022 and troughed at $864.4 million in Q4 2024.
• A 5-year average of $1.0 billion and a median of $988.4 million in 2022 frame the typical range for Current Assets.
• On a YoY basis, Current Assets climbed as much as 52.95% in 2022 and fell as far as 30.96% in 2022.
• A 5-year view of Current Assets shows it stood at $1.4 billion in 2022, then slipped by 22.46% to $1.1 billion in 2023, then retreated by 18.77% to $864.4 million in 2024, then climbed by 4.19% to $900.7 million in 2025, then climbed by 13.56% to $1.0 billion in 2026.
• Business Quant data shows DNLI's Current Assets at $1.0 billion in Q1 2026, $900.7 million in Q4 2025, and $882.6 million in Q3 2025.